Earlier today, Zelda Therapeutics Ltd. (ASX:ZLD)(OTC:ZLDAF) announced the company has entered into a manufacturing and consulting agreement with Chilean pharmaceutical manufacturing group, Knop Laboratories.
Zelda has already partnered with Chilean non-profit group, Fundación Daya to conduct clinical trials of a cannabinoid-based therapy in patients with autism spectrum disorder, insomnia or dermatitis (eczema). The new partnership will enable Zelda to expedite the clinical trial process and it will allow for the potential of mass production in the event one or more of the clinical trials are successful.
About Knop Laboratories
Knop Laboratories was started in the 1920s to research and develop homeopathic and plant-based treatments. Since then, the company has built a state of the art pharmaceutical manufacturing facility that is GMP compliant and ISO 9001 accredited. Knop also has a pharmacy chain with numerous locations across Chile.
In Thursday's trading on the ASX, shares of Zelda Therapeutics gained 4.05%, closing the day at $0.0770 AUD. Trading volume on the ASX today was more than double times the company's 30-day average volume. On the U.S. OTC Markets, shares of Zelda are flat on the day. At the time of this writing, ZLDAF is bid at $0.058 and offered at $0.06.
View the original ASX announcement here.
We're expanding our coverage of the marijuana industry in Australia as well as Chile. To stay up to date, be sure to subscribe to our free Australian cannabis email newsletter and check back soon for more coverage of developments in Chile. Also, don't forget to connect with The Daily Marijuana Observer on Facebook, Twitter and Instagram.
The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.